Senti Biosciences (SNTI) Competitors $4.85 +0.42 (+9.55%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. RNAC, CKPT, PHAT, RGNX, BNTC, ALLO, ORKA, TECX, TKNO, and TRDAShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Cartesian Therapeutics (RNAC), Checkpoint Therapeutics (CKPT), Phathom Pharmaceuticals (PHAT), REGENXBIO (RGNX), Benitec Biopharma (BNTC), Allogene Therapeutics (ALLO), Oruka Therapeutics (ORKA), Tectonic Therapeutic (TECX), Alpha Teknova (TKNO), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Cartesian Therapeutics Checkpoint Therapeutics Phathom Pharmaceuticals REGENXBIO Benitec Biopharma Allogene Therapeutics Oruka Therapeutics Tectonic Therapeutic Alpha Teknova Entrada Therapeutics Senti Biosciences (NASDAQ:SNTI) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk. Does the media favor SNTI or RNAC? In the previous week, Senti Biosciences had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 1 mentions for Cartesian Therapeutics. Senti Biosciences' average media sentiment score of 1.31 beat Cartesian Therapeutics' score of 0.88 indicating that Senti Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, SNTI or RNAC? Senti Biosciences has higher earnings, but lower revenue than Cartesian Therapeutics. Senti Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenti Biosciences$2.56M49.30-$71.06M-$12.03-0.40Cartesian Therapeutics$38.91M7.96-$219.71M-$52.83-0.23 Which has more volatility & risk, SNTI or RNAC? Senti Biosciences has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Do insiders & institutionals believe in SNTI or RNAC? 25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 10.7% of Senti Biosciences shares are held by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in SNTI or RNAC? Cartesian Therapeutics received 34 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 40.00% of users gave Senti Biosciences an outperform vote. CompanyUnderperformOutperformSenti BiosciencesOutperform Votes440.00% Underperform Votes660.00% Cartesian TherapeuticsOutperform Votes3895.00% Underperform Votes25.00% Is SNTI or RNAC more profitable? Senti Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Senti BiosciencesN/A -154.84% -77.42% Cartesian Therapeutics -510.72%N/A -6.03% Do analysts prefer SNTI or RNAC? Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 106.06%. Cartesian Therapeutics has a consensus target price of $42.67, suggesting a potential upside of 256.74%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCartesian Therapeutics beats Senti Biosciences on 10 of the 18 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.20M$2.91B$5.36B$7.58BDividend YieldN/A1.91%5.44%4.33%P/E Ratio-0.3130.5222.0318.15Price / Sales49.30475.50391.69105.06Price / CashN/A168.6838.2034.62Price / Book0.323.726.774.18Net Income-$71.06M-$72.06M$3.21B$247.59M7 Day Performance25.08%9.30%4.42%4.70%1 Month Performance30.46%-8.77%-6.63%-4.87%1 Year Performance72.77%-20.75%15.81%3.56% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences3.0654 of 5 stars$4.85+9.5%$10.00+106.1%+48.2%$126.20M$2.56M-0.314Positive NewsRNACCartesian Therapeutics1.8586 of 5 stars$13.00+21.8%$42.14+224.2%-43.5%$336.79M$38.91M-0.2564CKPTCheckpoint Therapeutics1.5493 of 5 stars$4.01+0.5%$4.33+8.1%+181.5%$335.89M$41,000.00-2.1810PHATPhathom Pharmaceuticals3.5654 of 5 stars$4.63-5.1%$22.17+378.8%-55.6%$322.42M$55.25M-0.81110Analyst ForecastGap UpRGNXREGENXBIO4.5718 of 5 stars$6.33+7.5%$31.88+403.6%-44.0%$317.24M$83.33M-1.26370News CoveragePositive NewsBNTCBenitec Biopharma2.4773 of 5 stars$13.27+5.1%$24.71+86.2%+99.1%$311.20M$80,000.00-8.7920Positive NewsALLOAllogene Therapeutics2.9587 of 5 stars$1.43-1.4%$9.29+549.6%-52.2%$310.69M$22,000.00-0.92310News CoverageGap UpORKAOruka Therapeutics2.8753 of 5 stars$8.14+6.0%$39.86+389.6%N/A$304.77MN/A-1.30N/AGap UpTECXTectonic Therapeutic2.7484 of 5 stars$17.87+10.6%$77.75+335.1%N/A$301.59MN/A-3.03120Analyst ForecastNews CoveragePositive NewsGap UpTKNOAlpha Teknova1.444 of 5 stars$5.67+1.4%$8.50+49.9%+267.4%$298.71M$37.75M-7.66240News CoverageGap UpTRDAEntrada Therapeutics2.8043 of 5 stars$7.92+0.3%$25.67+224.1%-32.4%$297.75M$210.78M4.98110Positive News Related Companies and Tools Related Companies Cartesian Therapeutics Alternatives Checkpoint Therapeutics Alternatives Phathom Pharmaceuticals Alternatives REGENXBIO Alternatives Benitec Biopharma Alternatives Allogene Therapeutics Alternatives Oruka Therapeutics Alternatives Tectonic Therapeutic Alternatives Alpha Teknova Alternatives Entrada Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNTI Stock Free SNTI Stock Alerts